Hemophilia B is a genetic disorder that affects how well your blood clots. Treatment includes supplementing the protein factor IX, but new therapies may offer alternative ways to manage factor IX ...

According to the Kebbi Sickle Cell Association (KESCA), there are 138,000 children born with sickle cell disease every year ...

Six months after scoring FDA approval for hemophilia B gene therapy Beqvez, Pfizer has earned a nod from the U.S. regulator for another of its products in the indication. On Friday, the FDA signed ...

Born in Bihar’s Patna, Chandan suffers from hemophilia A, a rare genetic disorder in which the blood doesn’t clot properly. “When I think about my childhood days. It’s all dark.

The approval is based on an open-label, multicenter study of 116 adult and pediatric male patients with either severe hemophilia A or severe hemophilia B, both without inhibitors. For the first ...

Oct. 14, 2024 – The FDA has approved a new preventive treatment for people with certain types of hemophilia that can reduce bleeding episodes, sometimes down to just a few per year.

Oct. 11 (UPI) --Patients suffering from hemophilia received a "meaningful" advancement on Friday when federal regulators approved the first once-weekly treatment for the disease. Hympavzi ...

FDA approves Pfizer’s Hympavzi for routine prophylaxis in hemophilia A and B patients, offering a once-weekly dosing via auto-injector pen. Phase 3 trial showed Hympavzi reduced bleeding rates ...

HYMPAVZI’s approval is based on Phase 3 study results demonstrating substantial bleed reduction compared to routine prophylaxis and on-demand treatment in eligible patients with hemophilia A or ...

Marstacimab is the first subcutaneous option for hemophilia B, reducing reliance on frequent IV infusions and improving patient quality of life. The phase 3 BASIS trial showed marstacimab reduced ...

for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients 12 years of age and older with hemophilia A (congenital factor VIII deficiency ...

Pfizer Inc. has won regulatory approval for its hympavzi drug as a treatment for hemophilia A or B without inhibitors — making it the first antitissue-factor pathway inhibitor to be allowed for ...